Christoph Höeller

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.7K citations

Medicine, Oncology, Pharmacotherapy +16

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

James Larkin, David R. Minor, Sandra P. D’Angelo et al. · Journal of Clinical Oncology · 2017 · 510 citations · Full text

Medicine, Oncology, Pharmacology +17

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert et al. · The Lancet Oncology · 2017 · 495 citations

Pharmacy, Oncology, Pharmacotherapy +11

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

Burkhard Jansen, Volker Wacheck, Elisabeth Heere‐Ress et al. · The Lancet · 2000 · 481 citations

Medicine, Cancer Biology, Oncology +14

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17